Skip to main content

The immunologic response to severe acute respiratory syndrome coronavirus 2.

Publication ,  Journal Article
Le, NK; Kaman, K; Martin, HC; Mullur, J; Stenehjem, KK; Coomar, L; Bahar, B; Dutta, M; Izurieta, R; Brooks, JP
Published in: Allergy Asthma Proc
November 1, 2021

Background: The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated the worst global pandemic in a century, which has caused millions of infections and deaths as well as massive economic repercussions. Objective: As with any pathogenic virus, it is crucial to understand its unique interactions with the human immune system so that pharmaceutical and prophylactic interventions can be deployed to effectively control the pandemic. Methods: A literature search by using PubMed was conducted in 2020 with variants of the terms "COVID-19," "SARS-CoV-2," and "immunological response." English language articles that presented original data about the immunologic response to coronavirus disease 2019 (COVID-19) were selected for review. This article reviewed the current understanding of the innate and adaptive immune responses to SARS-CoV-2 infection, including their relationship to current therapeutic and diagnostic strategies. Results: SARS-CoV-2 uses several unique molecular techniques to evade detection by the innate immune system early in the course of infection, and upregulation of these innate immune pathways may possibly accelerate the time to recovery and prevent severe disease. Although the majority of cases results in the patients' recovery, a significant proportion of infections result in deaths prompted by the host's inflammatory overreaction to the infection, a response that can be attenuated with corticosteroids and potentially other immune modulators. Conclusion: Current work by the scientific community to further understand how SARS-CoV-2 interacts with the human immune system will be invaluable to our response and preparedness for future coronavirus pandemics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Allergy Asthma Proc

DOI

EISSN

1539-6304

Publication Date

November 1, 2021

Volume

42

Issue

6

Start / End Page

495 / 505

Location

United States

Related Subject Headings

  • Spike Glycoprotein, Coronavirus
  • SARS-CoV-2
  • Pandemics
  • Immunity, Innate
  • Immune System
  • Humans
  • Disease Susceptibility
  • COVID-19
  • Angiotensin-Converting Enzyme 2
  • Adaptive Immunity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Le, N. K., Kaman, K., Martin, H. C., Mullur, J., Stenehjem, K. K., Coomar, L., … Brooks, J. P. (2021). The immunologic response to severe acute respiratory syndrome coronavirus 2. Allergy Asthma Proc, 42(6), 495–505. https://doi.org/10.2500/aap.2021.42.210077
Le, Nicole K., Kelsey Kaman, Hannah C. Martin, Jyotsna Mullur, Kristen K. Stenehjem, Lokesh Coomar, Burak Bahar, Mudit Dutta, Ricardo Izurieta, and Joel P. Brooks. “The immunologic response to severe acute respiratory syndrome coronavirus 2.Allergy Asthma Proc 42, no. 6 (November 1, 2021): 495–505. https://doi.org/10.2500/aap.2021.42.210077.
Le NK, Kaman K, Martin HC, Mullur J, Stenehjem KK, Coomar L, et al. The immunologic response to severe acute respiratory syndrome coronavirus 2. Allergy Asthma Proc. 2021 Nov 1;42(6):495–505.
Le, Nicole K., et al. “The immunologic response to severe acute respiratory syndrome coronavirus 2.Allergy Asthma Proc, vol. 42, no. 6, Nov. 2021, pp. 495–505. Pubmed, doi:10.2500/aap.2021.42.210077.
Le NK, Kaman K, Martin HC, Mullur J, Stenehjem KK, Coomar L, Bahar B, Dutta M, Izurieta R, Brooks JP. The immunologic response to severe acute respiratory syndrome coronavirus 2. Allergy Asthma Proc. 2021 Nov 1;42(6):495–505.

Published In

Allergy Asthma Proc

DOI

EISSN

1539-6304

Publication Date

November 1, 2021

Volume

42

Issue

6

Start / End Page

495 / 505

Location

United States

Related Subject Headings

  • Spike Glycoprotein, Coronavirus
  • SARS-CoV-2
  • Pandemics
  • Immunity, Innate
  • Immune System
  • Humans
  • Disease Susceptibility
  • COVID-19
  • Angiotensin-Converting Enzyme 2
  • Adaptive Immunity